Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.

@article{Birkhaeuser2013DendriticCI,
  title={Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.},
  author={Frederic D Birkhaeuser and Richard Chikara Koya and Caleb Neufeld and Edward N Rampersaud and Xuyang Lu and Ewa D. Micewicz and Thinle Chodon and Mohammad S Atefi and Nils Kroeger and G. V. R. Chandramouli and Gang Li and Jonathan Said and William H. Mcbride and Fairooz F. Kabbinavar and Antoni Ribas and Allan J. Pantuck and Arie S. Belldegrun and Joseph Riss},
  journal={Journal of immunotherapy},
  year={2013},
  volume={36 2},
  pages={102-11}
}
The dendritic cell vaccine DC-Ad-GM·CAIX is an active, specific immunotherapy with the potential of providing a safe and effective therapy against renal cell carcinoma (RCC). Using immunocompetent Balb/c mouse models we tested the efficacy and mechanism of the vaccine to prevent and treat the growth of a syngeneic RCC (RENCA) engineered to overexpress the human TAA carbonic anhydrase IX (NPR-IX). In a prevention model, NPR-IX tumor development was specifically and significantly delayed by 13… CONTINUE READING